Artelo Biosciences, Inc., a clinical stage biopharmaceutical company, develops and commercializes therapeutics that target lipid-signaling pathways in the United States. The company's product candidate pipeline includes ART27.13, a synthetic dual cannabinoid G protein-coupled receptor agonist, which is in Phase 1b/2a clinical trial for the treatment of cancer-related anorexia; and ART12.11, a cocrystal composition of cannabidiol and tetramethylpyrazine for the treatment anxiety, depression, post-traumatic stress disorder PTSD, epilepsy and insomnia, and other potential indications. It also offers ART26.12, a fatty acid binding protein 5 inhibitor for treating chemotherapy induced peripheral neuropathy, diabetic neuropathy, prostate cancer and breast cancer, pain, dermatologic conditions, and anxiety disorders. The company was formerly known as Reactive Medical Inc. and changed its name to Artelo Biosciences, Inc. in April 2017. Artelo Biosciences, Inc. was incorporated in 2011 and is based in Solana Beach, California.…
Artelo Biosciences Provides Business Update and Reports 2026 Third Quarter Financial Results
Artelo Biosciences (NASDAQ: ARTL) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 7 employees.
The shares were at 1.390 USD on 20 November 2026, down 97.6% over 52 weeks. Its 52-week range is 1.310 USD to 179.19 USD: the price is 99.2% below the high and 6.1% above the low.
Its market capitalisation is 1.30M USD.
Artelo Biosciences reports an operating margin of 0.0%.
It holds more cash than debt, a net cash position of 4.15M USD. Its Piotroski F-score is 1 out of 9, a weak reading of its financial health.